Oriheal Opthovet MKT (5ml) is a prescription-strength, dual-action veterinary ophthalmic solution engineered to treat surface bacterial infections accompanied by acute inflammation, discomfort, and severe eye pain in dogs and cats. The advanced formulation combines a fourth-generation fluoroquinolone antibiotic with a powerful non-steroidal anti-inflammatory drug (NSAID): Moxifloxacin Hydrochloride (0.5% w/v) and Ketorolac Tromethamine (0.5% w/v).

Each active ingredient targets a distinct component of traumatic or infectious ocular conditions. Moxifloxacin delivers broad-spectrum bactericidal activity against a wide range of Gram-positive and Gram-negative bacteria by disrupting critical enzymes needed for bacterial DNA replication. Complementing this, Ketorolac Tromethamine functions as a potent topical NSAID that blocks cyclooxygenase (COX) enzymes to halt prostaglandin synthesis. This directly alleviates severe ocular pain, burning, and swelling without the systemic or local complications associated with corticosteroids. In companion animal medicine, Opthovet MKT is clinically indicated for mixed bacterial infections, severe conjunctivitis, and seasonal eye allergies. It is also an essential tool for managing post-operative pain and inflammation following cataract or corneal surgeries.

Critical Safety Contraindication: Unlike standard ophthalmic NSAIDs, which are sometimes used carefully under tight veterinary monitoring to control uveitis, combination antibiotic-NSAID drops like Opthovet MKT are strictly contraindicated in cases of deep or active corneal ulcers. Ketorolac can delay corneal re-epithelialization, increase the risk of corneal melting, and mask pain that would otherwise signal a worsening ulcer. A veterinarian must perform a fluorescein stain test to confirm the cornea is completely intact before this medication is administered.